Teladoc (TDOC) AI Stock Analysis

• Market Cap: $1.21B
• Dividend Yield: N/A
• Average Volume (3M): 7.17M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.39
• Revenue Growth: -2.57%
• EPS Growth: 79.86%
• Country: US
• Employees: 4,620
• Sector: Healthcare
• Sector Strength: 43
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.19
• Shares Outstanding: 176,690,660
• 10 Day Avg. Volume: 8,205,535
• 30 Day Avg. Volume: 7,171,294
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.56
• Enterprise Value/Revenue: 0.74
• Enterprise Value/Gross Profit: 1.06
• Enterprise Value/Ebitda: -31.63
• 1Y Price Target: $8.86
• Price Target Upside: 21.37% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 14

• Rating: 44 Neutral
• Price Target: $7.00 ▼(-4.11% Downside)

Teladoc's overall stock score is primarily impacted by weak financial performance and challenging valuation metrics. While there are positive aspects such as a high gross profit margin and international growth, the bearish technical indicators and negative P/E ratio weigh heavily, suggesting cautious investor sentiment. The earnings call provides some optimism, but significant challenges remain, particularly in the BetterHelp segment.

Positive Factors

Earnings

Teladoc reported a good quarter relative to guidance, exceeding the Street on both revenue and EBITDA.

International Growth

Strong IC results were reported, with mid-teens international growth and raised guidance.

Negative Factors

Churn Rates

BetterHelp faced macro headwinds, leading to ongoing elevated churn rates.

Margin Pressure

There is caution on the near-term trajectory of the business and an expectation of downward pressure to margins as Teladoc invests for future growth.

Teladoc Business Overview & Revenue Model

Company Description

Teladoc Health, Inc. provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions. It offers a range of programs and services, including primary and specialty care telehealth solutions, chronic condition management, expert medical services, mental health solutions, and platform and program services. The company serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. It offers its products and services under the Teladoc, Livongo, and BetterHelp brands. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. The company was incorporated in 2002 and is headquartered in Purchase, New York.

How the Company Makes Money

Teladoc generates revenue through a subscription-based model and per-visit fees. Its primary revenue streams include membership fees from health plans, employers, and health systems, which provide access to its telehealth services for their members. Additionally, Teladoc earns revenue from pay-per-visit consultations where patients pay for individual visits to healthcare providers. The company has established significant partnerships with insurance companies and employers, enhancing its reach and utilization. Moreover, Teladoc has expanded its offerings through acquisitions and collaborations, further diversifying its revenue streams and enhancing its service capabilities.

Teladoc Financial Statement Overview

Summary

Teladoc faces profitability challenges with negative net profit margins and high leverage, but positive free cash flow and a stable equity base offer some financial resilience.

Income Statement

Teladoc has shown fluctuating revenue growth, with a decline from 2023 to the TTM period. The gross profit margin is stable at around 66-67%, but the net profit margin remains negative, indicating ongoing losses. EBIT and EBITDA margins are also negative, reflecting operational challenges.

Balance Sheet

The debt-to-equity ratio is relatively high, suggesting considerable leverage, but the equity ratio demonstrates a stable equity base. The ROE remains negative due to continuous net losses, which indicates profitability concerns.

Cash Flow

Free cash flow has been positive in the TTM period, showing signs of improvement. The operating cash flow to net income ratio is favorable, suggesting a good cash conversion from operations despite negative net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.54B	2.57B	2.60B	2.41B	2.03B	1.09B
Gross Profit	1.79B	1.82B	1.84B	1.66B	1.38B	703.13M
EBITDA	-59.67M	-587.01M	154.00M	-13.38B	-84.67M	-438.01M
Net Income	-207.36M	-1.00B	-220.37M	-13.66B	-428.79M	-485.14M
Balance Sheet
Total Assets	2.89B	3.52B	4.39B	4.35B	17.73B	17.76B
Cash, Cash Equivalents and Short-Term Investments	679.62M	1.30B	1.12B	918.18M	896.02M	786.57M
Total Debt	1.03B	1.58B	1.59B	1.57B	1.27B	1.47B
Total Liabilities	1.47B	2.03B	2.07B	2.04B	1.69B	1.87B
Stockholders Equity	1.42B	1.49B	2.33B	2.31B	16.05B	15.88B
Cash Flow
Free Cash Flow	238.64M	282.89M	193.67M	16.53M	130.06M	-79.55M
Operating Cash Flow	303.43M	293.68M	350.02M	189.29M	193.99M	-53.51M
Investing Cash Flow	-243.76M	-124.05M	-156.35M	-167.74M	-72.98M	-590.98M
Financing Cash Flow	-546.41M	8.31M	10.85M	6.50M	40.95M	859.14M

Teladoc Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 7.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TDOC, the sentiment is Neutral. The current price of 7.3 is below the 20-day moving average (MA) of 7.51, below the 50-day MA of 7.69, and below the 200-day MA of 8.80, indicating a bearish trend. The MACD of -0.24 indicates Positive momentum. The RSI at 46.35 is Neutral, neither overbought nor oversold. The STOCH value of 60.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TDOC.

Teladoc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HSTM	69 Neutral	$768.89M	38.99	5.81%	0.45%	3.50%	13.99%
EVH	51 Neutral	$1.03B	―	-13.38%	―	-6.71%	-71.40%
SOPH	51 Neutral	$209.85M	―	-74.09%	―	7.31%	-7.49%
Sector *	51 Neutral	$7.44B	-0.20	-46.00%	2.27%	22.80%	-2.27%
AMWL	50 Neutral	$117.43M	―	-38.52%	―	5.83%	67.49%
HCAT	44 Neutral	$205.84M	―	-28.42%	―	5.55%	-0.99%
TDOC	44 Neutral	$1.21B	―	-14.18%	―	-2.57%	79.86%

Teladoc Corporate Events

Teladoc Secures $300M Credit Facility with JPMorgan

On July 17, 2025, Teladoc Health, Inc. entered into a credit agreement with JPMorgan Chase Bank, establishing a $300 million senior secured revolving credit facility to enhance financial and operational flexibility. The facility, which has a five-year term, is designed to support Teladoc’s strategic initiatives without immediate borrowing plans, and includes financial covenants to maintain leverage and interest coverage ratios.

The most recent analyst rating on (TDOC) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Teladoc stock, see the TDOC Stock Forecast page.

Teladoc Approves Key Proposals at Annual Meeting

On May 22, 2025, Teladoc Health, Inc. held its Annual Meeting of Stockholders, where several key proposals were approved. Notably, the stockholders approved an amendment to the 2023 Incentive Award Plan, increasing the number of shares available for issuance by 6,850,000. Additionally, the election of directors and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, were confirmed. These decisions are expected to impact the company’s strategic direction and operational governance.

The most recent analyst rating on (TDOC) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Teladoc stock, see the TDOC Stock Forecast page.